Elizabeth Holmes raised $945 million for a blood-testing device that didn't work. The fraud required something beyond one charismatic founder: a board of directors assembled from secretaries of state, four-star generals, and senators — none of whom had a single day of diagnostics expertise — who lent credibility the company had never earned. This map traces the documented relationships between Holmes, her board, her investors, the whistleblowers who tried to stop it, and the regulators who eventually did.
Elizabeth Holmes founded Theranos in 2003 at age 19, leaving Stanford after her freshman year. The company's stated mission: revolutionize blood diagnostics by running comprehensive panels from a finger-prick sample, eliminating the need for venipuncture. The device was called the Edison. The promise was real disruption — faster, cheaper, less invasive testing that could democratize healthcare.
Holmes was convicted on four counts of wire fraud and conspiracy by a federal jury on January 3, 2022 — specifically, defrauding investors. She was acquitted on the patient fraud counts. On November 18, 2022, she was sentenced to 135 months (11.25 years) in federal prison. She began serving her sentence on May 30, 2023. Sunny Balwani, who served as President and COO from 2009, was convicted separately on all 12 counts and sentenced to 155 months.
The convictions rest on documented evidence: falsified investor presentations, fake pharmaceutical company validation reports assembled by Theranos staff but bearing pharma logos, false claims about DoD battlefield deployment, and revenue projections the defendants knew were fabricated. The SEC complaint (March 2018) and DOJ indictment (June 2018) are both public record and form the primary source layer of this investigation.
The SEC complaint documents that Theranos distributed binders to investors containing pharma company logos on what appeared to be independent validation reports. Those reports were written by Theranos staff, not the pharma companies whose names they bore. This was not aggressive marketing — the DOJ indictment charges it as a knowing, intentional misrepresentation. The binders also included media coverage from the Wall Street Journal, Wired, and Fortune — reporting that Holmes knew at the time was based on information she had provided and knew to be false.[1]
Theranos told investors it had a profitable business relationship with the Department of Defense, and that its technology had been deployed on the battlefield in Afghanistan and on medevac helicopters. In truth, Theranos' technology was never deployed by the U.S. Department of Defense.
The indictment documents that Holmes and Balwani represented to investors that Theranos would generate over $100 million in revenues in 2014. In truth, Theranos generated approximately $100,000 — not $100 million — in revenue from operations that year. A factor of one thousand. This is not forecast error. The defendants knew the real figures when they made the projections.[2]
The device at the center of the company's claims — the Edison, TSPU, or "minilab" as it was variously named — was alleged by the indictment to perform a limited number of tests (not the comprehensive panel claimed), produce accuracy and reliability problems the defendants were aware of, and be slower than some competing devices. For the vast majority of tests run under the Theranos brand, Theranos used commercially available third-party analyzers — not the Edison. Patients were billed for Theranos technology they were not receiving.[3]
The Centers for Medicare & Medicaid Services (CMS) conducted lab inspections in 2015 and 2016. In 2016, CMS findings led to the revocation of Theranos's CLIA certification and a two-year ban on Holmes operating or owning a laboratory. FDA inspection reports from 2014 and 2015, also public record, documented that Theranos's blood collection containers were "not validated under actual or simulated use conditions." These are regulatory determinations, not allegations — they carry the weight of federal findings.[4]
Walgreens deployed Theranos blood-testing centers in approximately 40 of its stores in California and Arizona, advertising to patients that the Edison device was performing their tests. Walgreens later sued Theranos; the suit was settled. Safeway invested roughly $350 million to retrofit stores for Theranos wellness centers before the partnership collapsed. Both companies relied on representations from Holmes and Balwani that the indictment documents as false.[5]
"The board's high-profile reputation helped squelch doubts and deflect criticism for nearly two decades. The board was not assembled for oversight — it was assembled to raise money and attract publicity."
Escalon Business Review analysis, 2021 — drawing on trial testimony and corporate filingsThis is the documented structural failure at the center of the Theranos story, and it is distinct from Holmes's fraud itself. The board — assembled by George Shultz beginning in 2011 — included former Secretary of State Henry Kissinger, former Secretary of Defense William Perry, retired Marine General James Mattis, retired Navy Admiral Gary Roughead, former Senator Sam Nunn, former Senator and heart surgeon Bill Frist, former Wells Fargo CEO Richard Kovacevich, and former Bechtel CEO Riley Bechtel.
Not one of these individuals had expertise in blood diagnostics, laboratory medicine, or medical device engineering. The sole exception was Bill Frist, who trained as a heart and lung transplant surgeon before entering politics — a background irrelevant to the accuracy claims Theranos was making. Theranos did not assemble a medical advisory board until 2016 — after both the CMS investigation and the DOJ criminal investigation had already begun.[6]
At trial, General James Mattis — who later served as Secretary of Defense under President Trump — testified that Elizabeth Holmes was his primary source for all information about the company and its technology. A presentation Holmes made to the board, which Mattis submitted as a trial exhibit, claimed the technology had been validated by both the FDA and the World Health Organization. Neither claim was true. The board did not independently verify either claim.[7]
Tyler Shultz, grandson of board member George Shultz, joined Theranos in 2013 as a research engineer on the assay validation team. He documented quality control failures — results being altered, faulty data being erased, patients receiving inaccurate findings. He took his concerns to Holmes directly. She declined a second meeting and routed his complaint to Balwani, who responded by insulting and threatening him in writing.
Tyler Shultz then took his concerns to his grandfather George Shultz, who rejected them. George Shultz told his grandson that Holmes had persuaded him the technology worked and that Tyler was simply wrong. When Tyler contacted Wall Street Journal reporter John Carreyrou, Theranos lawyers convened a meeting at George Shultz's house and pressured Tyler to sign a confidentiality agreement. He refused.[8]
The documented record permits a specific structural analysis without requiring speculation about motive.
The board was assembled to credentialize military and government contracts. Theranos's most significant growth narrative — the DoD battlefield deployment claim — required credibility with military and government decision-makers. William Perry had been Secretary of Defense. James Mattis was an active four-star Marine general during part of his Theranos board tenure. The board composition directly matched the business development narrative, and the indictment documents that narrative as fabricated.
Private company structure removed disclosure requirements. Theranos was never publicly traded. It had no obligation to file with the SEC, publish audited financials, or disclose the Edison's actual test performance to the public. The sophisticated investors who committed hundreds of millions of dollars — the Walton family ($150 million), Rupert Murdoch ($120+ million), Betsy DeVos ($100 million) — were investing in a private company whose technology claims could not be independently audited without site access Holmes controlled.[9]
Media halo preceded regulatory scrutiny by years. Forbes named Holmes the youngest female self-made billionaire. Fortune, Wired, and the Wall Street Journal (before Carreyrou's investigation) ran celebratory profiles. Holmes appeared on the cover of major publications. This media profile was itself used as a fundraising instrument — investor binders included the favorable media coverage. The SEC complaint documents this explicitly.
Reputation management was active and documented. Following the Carreyrou WSJ story in October 2015, former employees of reputation management firm Status Labs stated that Theranos had hired the firm to discreetly remove mentions of the WSJ reporting from Theranos's Wikipedia article — a violation of Wikipedia's terms of use. Theranos also dispatched lawyers against whistleblowers and sources in an attempt to suppress reporting.[10]
The fraud is documented and adjudicated. But the board failure has not been. No board member faced civil or criminal liability for the oversight failure. James Mattis served as Secretary of Defense of the United States from 2017 to 2019 while the criminal investigation of the company he had recently served was underway. George Shultz died in 2021 before the trial concluded. The investors who lost hundreds of millions in a fraud enabled in part by the board they relied on received no remedy from the board members themselves.
The structural question the Theranos case documents is this: a board assembled without domain expertise, for the purpose of credentialing a narrative to investors and government contacts, exercised no independent verification of any technology claim for the entirety of the company's commercial life. The trial record confirms this. It is not an allegation. It is the documented record of what a board of former secretaries of state, generals, and senators collectively failed to ask.